がん予防の個別化に向けたソリューションを開発している。多遺伝子リスクスコア（PRS）技術に基づき、がんの遺伝的要因を正確に検出し、早期発見や個別医療の実現を支援する。現在、乳がん、前立腺がん、小腸がん、悪性黒色腫（メラノ […]
●同社は多遺伝子リスクスコアを用いて癌の遺伝性素因を検出 ●検査結果をもとに、癌患者への個別医療の提供をサポート エストニアのヘルステック企業アンテゲネス（Antegenes）はこのほど、シードラウンドで230万ユーロの
| Cookie | 期間 | 説明 |
|---|---|---|
| cookielawinfo-checbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
| cookielawinfo-checbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
| cookielawinfo-checbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
| cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
| cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
| viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
